ALLO News and Press, Allogene Therapeutics Inc. From 01/23/23

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming invest...

Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...

Baird has upgraded Allogene Therapeutics ( NASDAQ: ALLO ) to outperform from neutral. The firm has a price target of $12 (~107% upside based on Thursday's close). Analyst Jack Allen said that Allogene ( ALLO ) has differentiated itself from other allogeneic cell therapy d...

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that David Chang, M.D., Ph.D., President, Chief...

Summary CRISPR Therapeutics AG is a gene editing company based on CRISPR/Cas9 technology. CRISPR method seems to be the preferred in Gene Editing. CRSP has a rich pipeline. CRISPR seems to be the preferable Gene Editing Method and CRISPR Therapeutics AG ( CRSP ) could ...

Cell therapy developer Allogene Therapeutics ( NASDAQ: ALLO ) ended three consecutive days of gains after announcing the resignation of Rafael Amado, who functioned as the company’s Executive Vice President, Head of R&D, and Chief Medical Officer. In a release announcing th...

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Zachary J. Roberts M.D., Ph....

BofA Securities has downgraded Allogene Therapeutics ( NASDAQ: ALLO ) to underperform citing a lack of catalysts and concerns over the competitiveness of its CAR-T therapy ALLO-715. The firm has cut its price target to $9 from $24 (~3% upside based on Friday's close). The stock is...

Hematology Franchise: Lead CD19 and BCMA Programs Demonstrated Deep, Durable Responses CD19 Program: Phase 1 Studies Support Ongoing ALLO-501A Potentially Pivotal Phase 2 Trial in Relapsed/Refractory (R/R) Large B Cell Lymphoma (LBCL) One-Time Cell Dosing with Proprietary Lymp...